—
C+
C+ The full Closelooknet — membership. Open the C+ overview

BridgeBio Pharma Inc (BBIO) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for BBIO, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.34 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How BBIO has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.34 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), BridgeBio Pharma Inc moved 0.34% on average · correlation 0.07 · higher than 33% of US names
  • Beta, last 3 months 1.10 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.81% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.87% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BBIO on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — BridgeBio Pharma Inc

BBIO in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency. Several other drugs sit in Phase 3 trials, including treatments for achondroplasia, a calcium-related hormonal disorder and a muscular condition, alongside an early-stage gene therapy for Canavan disease. It works through licensing deals with larger pharmaceutical partners. It is based in Palo Alto, California.
Where it sits in the stack
BridgeBio Pharma has no seat in our index; it sits in the Healthcare sleeve of the diary's US universe, grouped there by sector and country rather than by any AI build-out layer.
Who it is priced against
Closelooknet's peer group here is scored Healthcare names based in the US, among them argenx, Medpace, BeiGene, Regeneron, Vertex and Corcept Therapeutics; the market also names Alnylam Pharmaceuticals as a comparison in genetic-disease drug development.
Why Closelooknet tracks it
BridgeBio Pharma carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.
What the diary watches
Whether the Phase 3 programmes for achondroplasia, the hormonal disorder and the muscular condition report results, since trial outcomes would reset the momentum reading.

BridgeBio Pharma Inc (BBIO) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Mizuho, 2026-09-01

The Street on this name

Analyst actions and the latest print for BBIO from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Mizuho — target 110 from 96 Target raised to $110 from $96 (+43.6% to spot) 2026-09-01

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-10-07

Quick answers

What is BridgeBio Pharma Inc (BBIO)?

BridgeBio Pharma Inc trades as BBIO on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is BBIO in a Closelooknet index?

Not currently — BridgeBio Pharma Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does BBIO trade against its moving averages?

Mixed moving-average stack: Trades -11.5% vs the 50-day and -8.9% vs the 200-day average, 28.3% below the 52-week high and +26.9% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does BridgeBio Pharma Inc compare with its peers?

Against its peer group (Biotechnology · US), BridgeBio Pharma Inc (BBIO) sits 28.3% below its 52-week high, 11.5% below its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to BBIO in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does BridgeBio Pharma Inc trade when bond yields rise?

Over the past year BridgeBio Pharma Inc had a beta of 0.34 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 33% of US names. On the 10 sessions in which long bonds fell most it moved −1.81% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does BridgeBio Pharma Inc do?

BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency. Several other drugs sit in Phase 3 trials, including treatments for achondroplasia, a calcium-related hormonal disorder and a muscular condition, alongside an early-stage gene therapy for Canavan disease. Closelooknet's peer group here is scored Healthcare names based in the US, among them argenx, Medpace, BeiGene, Regeneron, Vertex and Corcept Therapeutics; the market also names Alnylam Pharmaceuticals as a comparison in genetic-disease drug development.

Where does BridgeBio Pharma Inc sit in the AI build-out?

BridgeBio Pharma has no seat in our index; it sits in the Healthcare sleeve of the diary's US universe, grouped there by sector and country rather than by any AI build-out layer. BridgeBio Pharma carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no index seat and the diary has not yet quoted it.

What has Wall Street done on BridgeBio Pharma Inc recently?

The most recent analyst action on BridgeBio Pharma Inc on the Closelooknet wire is a price target by Mizuho on 2026-09-01 (target 110 from 96). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BBIO, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.